Ernexa Accelerates ERNA‑101 to Q3 IND Filing, Poised for First‑In‑Human Trial
Ernexa Therapeutics moves ERNA‑101 to Q3 IND filing, positioning its mRNA cell‑engineered therapy for first‑human trials and potential valuation boost.
3 minutes to read
Ernexa Therapeutics Inc
Ernexa Therapeutics Files Q1 2026 Report, Sets July 1 Proxy Meeting & Shares Financial Highlights
Ernexa Therapeutics’ Q1 2026 filing reveals key financials, upcoming July 1 shareholder meeting, and its mRNA‑based biotech strategy.
3 minutes to read
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split to Meet Nasdaq Requirements Amid Financial Concerns
Ernexa Therapeutics Inc. has announced a 1-for-15 reverse stock split to regain compliance with Nasdaq’s listing requirements, but the move raises concerns about the company’s financial health and market performance.
2 minutes to read